TransEnterix sells two Senhance Systems in December quarter for $3.3M
"2017 was a transformational year for TransEnterix that included the commencement of U.S. Senhance commercialization and progression towards the global commercialization of SurgiBot," said Todd Pope, President and CEO at TransEnterix. "We are very excited about the opportunity that lies ahead in 2018 as we look to build upon our momentum and drive the global adoption of the Senhance." During the quarter ending December 31, 2017, the company sold two Senhance Systems for total revenue of approximately $3.3M. Total 2017 revenue is approximately $7M, consensus $6.98M, a 360% increase over 2016, representing a total of five Senhance Systems: Europe (two), Asia (two, including one sale for which the revenue was not recognized in 2017) and the United States (one). The company currently has received one European Senhance System order that it expects to deliver and recognize revenue for in the quarter ending March 31, 2018.